Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck ( NYSE: MRK) has confirmed a deal worth around $10 billion to acquire Verona Pharma ( NASDAQ: VRNA ), a biotech firm ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker.

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.